Dissecting the Thrombopoietin Receptor: Functional Elements of the Mpl Cytoplasmic Domain (Tyrosine Phosphorylation͞thrombopoietin͞signal Transduction͞jak͞stat)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Steve Parmelee SENIOR COUNSEL
Steve Parmelee SENIOR COUNSEL Litigation Seattle [email protected] 206-883-2542 FOCUS AREAS EXPERIENCE Steve Parmelee is senior counsel in Wilson Sonsini Goodrich & Rosati's Seattle office. He Intellectual Property has over 25 years of experience in inter partes proceedings before the Patent Trial and Life Sciences Appeal Board (PTAB) of the U.S. Patent and Trademark Office (PTO). He has represented patent applicants in many patent interference proceedings at the PTAB. In addition, he has Litigation experience representing clients in the new post-grant trial proceedings that were enacted in Patents and Innovations the America Invents Act of 2011, including inter partes review (IPR) and covered business method (CBM) challenges to issued patents. Post-Grant Review Steve has acted as lead counsel in a number of patent interferences at the PTAB covering a wide range of technologies, including medical devices, photolithography, wireless security protocols, high-density recording media, and biotechnology. Notable cases include University of Washington v. Eli Lilly & Co., in which Steve represented the prevailing party in establishing the now-standard "two-way test" for declaring interferences, and Affymetrix v. Incyte, where he represented the prevailing party Affymetrix in a major gene array dispute. Steve has worked extensively on client patent portfolios in the areas of immunology, molecular biology, and infectious disease. He obtained patent protection for a licensee's immunotherapy product with sales of more than $1.3 billion per year, generating substantial royalties for the client. He also advises clients on freedom-to-operate issues and due diligence concerns prior to licensing, investments, or acquisitions. -
Printmgr File
NOTICE OF 2020 ANNUAL MEETING AND PROXY STATEMENT ANNUAL MEETING Friday, May 15, 2020 11:00 a.m. at Seattle Genetics Corporate Headquarters Building 3 21823 – 30th Drive SE Bothell, Washington 98021 Dear Fellow Shareholders: Seattle Genetics had a remarkable year in 2019 and entered 2020 as a multi-product oncology company. First, in collaboration with our partner Takeda, ADCETRIS® global sales exceeded $1 billion for the first time. ADCETRIS is an important medicine around the world for the treatment of patients with certain types of lymphoma. Second, we and our collaborator Astellas received FDA accelerated approval of PADCEVTM (enfortumab vedotin-ejfv) for adult patients with previously treated locally advanced or metastatic urothelial cancer, potentially changing the treatment paradigm for these patients with a high unmet need. The approval expanded our commercial portfolio and will diversify our revenues from product sales, adding to a strong ADCETRIS base. And third, we reported positive results from our tucatinib HER2CLIMB-01 pivotal trial, which supported marketing applications in the United States, Europe and other countries to treat patients with metastatic HER2-positive breast cancer. These submissions position tucatinib to be our third commercial product, if approved, and allow us to offer a new treatment option to thousands of patients globally who are in need of better therapies. In addition, we believe ADCETRIS, PADCEV and tucatinib have other therapeutic opportunities and are investing in broad development programs. We also continue to invest in research and development as it is the engine for our future growth. We are advancing a robust pipeline of new product candidates in clinical trials, with a focus on first-in-class or best-in-class targeted therapies for cancer. -
35 Years of Supporting Innovation 2015/2016 REPORT CEO’S Message
35 Years of Supporting Innovation 2015/2016 REPORT CEO’s Message Table of Contents Marking Washington Research Foundation’s 35th anniversary is a good opportunity to reflect on the depth of talent in our state and the importance of the work that we support. Grant Programs 1 We’ve had the privilege of working with Dr. Benjamin Hall [profile on page 2], whose yeast technology has improved Dr. Benjamin D. Hall Profile 2 the health of more than a billion people worldwide. We’ve supported some of the most exceptional young minds in the country through our partnership with the ARCS Foundation [see page 1]. We’ve given grants and made venture Grant Profiles 4 investments in some of the most innovative projects and startup companies to come out of our local, world-class research WRF Capital 8 institutions. Our focus on research in Washington means that we focus on some of the best researchers in the world. Tom Cable, Bill Gates Sr. and Hunter Simpson recognized this when they founded WRF in 1981. It was clear to Portfolio Company Profiles 9 them that the University of Washington and other local institutions were creating valuable intellectual property with the WRF Venture Center and potential to benefit the public and provide much-needed revenue for additional research. At the time, UW had neither WRF Research Services 12 the resources nor expertise to successfully license its inventions. WRF was created to fill that gap. Our activities have since expanded, and despite a lack of precedence to predict success, coupled with some lean early years, we Staff 13 have now earned more than $436 million in licensing revenue for the University of Washington and disbursed over Board of Directors 14 $66 million in grants to research institutions throughout the state. -
Signature , )9. I
D 1 5 i OMB No 1545-0047 ,x Form Return of Organization Exempt From Income Tax Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except black lung 2009 benefit trust or private foundation) Open to Public DePartme nt of the Treasu iniemai Revenue seivicery P The organization may have to use a copy of this retum to satisfy state reporting requirements Inspection A For the 2009 calendar year, or tax year beginning , 2009, and ending , 20 B chuck ii api-iiinbie Please C Nameoforganization WASHINGTON BIOTECHNOLOGY & D Employer ldentiflcatlon number Address use IRS change label or Doing Business As BIOMEDICAL ASSOCIATION 91-1453398 Name change pnnt or E Telephone number *VPS Initial retum See 2324Number EASTLAKE and street (or AVENUE P O box if mailEAST is not delivered to street address) IIIRoomlsurte (206) 732-6700 Specim: Terminated Instruc City or town, state or country, and ZIP + 4 Amended hons retum SEATTLE, WA 98 1 02 G Grossrecelpts S 1,434,257. Application FName and address of principal officer CHRISTOPHER RIVERA H(a) ls this a group retum for Yes X N9 pending altiliates? 2324 EASTLAKE AVENUE EAST #500 SEATTLE, WA 98102 H(b) Are all affiliates included? Yes N0 I Tax-exempt status X I501(c)( 6 ) 4 (insert no) I I4947(a)(1)or I I527 If *No," attach a list (see instructions) J Website: P WWW . WASHBIO . ORG HIC) Group exemption number b SummaryK Forrnoforganization X I Corporation I I TrustI I Association I I Other P I L Year of fomiation l990I M State of legal domicile WA 1 Bnefly descnbe the organization"s mission or most signiicant activities - - - PROMOTE CONTINUED INNOVATION AND RESPONSIBLE GROWTH IN THE BIUTECHNQEQQZ-1i1iI2-1?.1Q11IEI21913E-11599515155-EELF1113.5191?.9.F.1"f*.S.H.1.11Q1QI1- ...... -
Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?
cancers Review Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies? Klara Klein 1, Dagmar Stoiber 2, Veronika Sexl 1 and Agnieszka Witalisz-Siepracka 1,2,* 1 Department of Biomedical Science, Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria; [email protected] (K.K.); [email protected] (V.S.) 2 Department of Pharmacology, Physiology and Microbiology, Division Pharmacology, Karl Landsteiner University of Health Sciences, 3500 Krems, Austria; [email protected] * Correspondence: [email protected] or [email protected] Simple Summary: The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is aberrantly activated in many malignancies. Inhibition of this pathway via JAK inhibitors (JAKinibs) is therefore an attractive therapeutic strategy underlined by Ruxolitinib (JAK1/2 inhibitor) being approved for the treatment of myeloproliferative neoplasms. As a consequence of the crucial role of the JAK-STAT pathway in the regulation of immune responses, inhibition of JAKs suppresses the immune system. This review article provides a thorough overview of the current knowledge on JAKinibs’ effects on immune cells in the context of hematological malignancies. We also discuss the potential use of JAKinibs for the treatment of diseases in which lymphocytes are the source of the malignancy. Citation: Klein, K.; Stoiber, D.; Sexl, Abstract: The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway V.; Witalisz-Siepracka, A. Untwining propagates signals from a variety of cytokines, contributing to cellular responses in health and disease. Anti-Tumor and Immunosuppressive Gain of function mutations in JAKs or STATs are associated with malignancies, with JAK2V617F being Effects of JAK Inhibitors—A Strategy the main driver mutation in myeloproliferative neoplasms (MPN). -
August 2020 Asbmb Today 1 President’S Message
THE Careers ISSUE Connect your community with a virtual scientific event Interested in hosting a virtual event? The ASBMB is here to help. The ASBMB provides a platform to share scientific research and to discuss emerging topics and technologies in an interactive, virtual setting. When you host a virtual event with the ASBMB, your event will: n accommodate up to 500 attendees n be marketed to the ASBMB’s 11,000 members n reach the ASBMB’s network of journal authors and meeting attendees Learn more about how to submit your proposal at asbmb.org/meetings-events NEWS FEATURES PERSPECTIVES 2 30 66 PRESIDENT’S MESSAGE LEADERSHIP AFTER THE LONGEST MARCH, With challenges come opportunities ON THE CUTTING EDGE SCIENCE MARCHES ON An interview with Toni Antalis, 4 the ASBMB’s new president MEMBER UPDATE 69 34 BEING BLACK 10 JOB SEEKERS FEEL THE EFFECTS IN THE IVORY TOWER IN MEMORIAM OF THE PANDEMIC AND POLITICS 12 STUDENT CHAPTERS A virtual high school science fair Careers 13 42 How a research tech can work from NEWS home in the time of COVID-19 13 ASBMB launches industry advisory group 44 Grant writing tips for beginners 14 ASBMB receives NIH grant to promote faculty diversity 47 F(i/u)nding your next hypothesis 49 Illuminating leadership during crisis 16 51 My postdoc road was rocky — LIPID NEWS then the pandemic hit Organizing fat: Mechanisms of creating and organizing cellular lipid stores 53 How can labs reopen safely? 56 A year of unrest and grace — 18 reflections on my journey to tenure JOURNAL NEWS 18 How lipid droplets stay in shape 58 Think you’d like to move away 20 Sorting and secreting insulin from the bench? by expiration date 22 Proteomics reveals hallmarks of aging 60 Supporting Ph.D. -
James Kronstad Gives the 2010 Inaugural Neurological Infections
Oct 2010 Special Issue Editor: Dianne Langford, Ph.D. Associate Editor: Michael Nonnemacher, Ph.D. Assistant: Leslie Marshall, Ph.D. James Kronstad Gives the 2010 Inaugural Neurological Infections Lectureship Dianne Langford Ph.D., Philadelphia, PA he ISNV is proud to honor James Kronstad who will present the 2010 TNeurological Infections Lecture at the 10th International Symposium on NeuroVirology in Milan, Italy. Dr. Kronstad received a Ph.D. in Microbiology and Immunology from the University of Washington, which was followed by two years of postdoctoral studies with ZymoGenetics in Seattle and two years as a research biologist with the USDA at the University of Wisconsin. Currently, he is a Professor in the Department of Microbiology and Immunol - ogy at the University of British Columbia and serves as the Director of the Michael Smith Laboratories, an interdisciplinary research unit founded by the Nobel Prize-winning chemist Dr. Michael Smith. Dr. Kronstad is a Bur - roughs Wellcome Fund Scholar, a Fellow of the American Academy of Mi - crobiology, and a Fellow of the American Association for the Advancement of Science. In addition to these accomplishments, he previously served as chair of the NIH study section on AIDS, Opportunistic Infections, and Cancer (AOIC) (2008-2010). As a leader in the field of fungal pathogenesis, Dr. Kronstad has con - tributed significantly to our understanding of the virulence mechanisms of fungal pathogens, their responses to anti-fungal therapeutics and aspects of fungal co-infection with HIV. In addition, work from Kronstad’s laboratory has uncovered important fungal survival adaptations to the host environ - ment. Dr. Kronstad’s research program focuses on the molecular genetic and genomic analysis of virulence in the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. -
Src Directly Tyrosine-Phosphorylates STAT5 on Its Activation Site and Is Involved in Erythropoietin-Induced Signaling Pathway
Oncogene (2001) 20, 6643 ± 6650 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway Yuichi Okutani1, Akira Kitanaka1, Terukazu Tanaka*,2, Hiroshi Kamano6, Hiroaki Ohnishi3, Yoshitsugu Kubota4, Toshihiko Ishida1 and Jiro Takahara5 1First Department of Internal Medicine, Kagawa Medical University, Kagawa 761-0793, Japan; 2Environmental Health Sciences, Kagawa Medical University, Kagawa 761-0793, Japan; 3Laboratory Medicine, Kagawa Medical University, Kagawa 761-0793, Japan; 4Transfusion Medicine, Kagawa Medical University, Kagawa 761-0793, Japan; 5Kagawa Medical University, Kagawa 761- 0793, Japan; 6Health Science Center, Kagawa University, Kagawa 760-8521, Japan Signal transducers and activators of transcription Growth and dierentiation of hematopoietic cells are (STAT) proteins are transcription factors activated by regulated by the interaction of cell surface receptors phosphorylation on tyrosine residues after cytokine with their speci®c cytokines or growth factors. While stimulation. In erythropoietin receptor (EPOR)-mediated some of these receptors transmit signals via their signaling, STAT5 is tyrosine-phosphorylated by EPO intrinsic protein tyrosine kinase (PTK) activity, others stimulation. Although Janus Kinase 2 (JAK2) is reported use cytoplasmic non-receptor PTK for mediating to play a crucial role in EPO-induced activation of signals (van der Geer et al., 1994). The binding of STAT5, it is unclear whether JAK2 alone can tyrosine- erythropoietin (EPO) to an erythropoietin receptor phosphorylate STAT5 after EPO stimulation. Several (EPOR) which does not contain any intrinsic PTK studies indicate that STAT activation is caused by activity induces rapid and transient tyrosine phosphor- members of other families of protein tyrosine kinases ylation of intracellular proteins (Constantinescu et al., such as the Src family. -
Interpretation of Cytokine Signaling Through the Transcription Factors STAT5A and STAT5B
Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B Lothar Hennighausen1 and Gertraud W. Robinson Laboratory of Genetics and Physiology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA Transcription factors from the family of Signal Trans- the “wrong” STATs and thus acquire inappropriate cues. ducers and Activators of Transcription (STAT) are acti- We propose that mice with mutations in various com- vated by numerous cytokines. Two members of this fam- ponents of the JAK–STAT signaling pathway are living ily, STAT5A and STAT5B (collectively called STAT5), laboratories, which will provide insight into the versa- have gained prominence in that they are activated by a tility of signaling hardware and the adaptability of the wide variety of cytokines such as interleukins, erythro- software. poietin, growth hormone, and prolactin. Furthermore, constitutive STAT5 activation is observed in the major- ity of leukemias and many solid tumors. Inactivation Historical perspective studies in mice as well as human mutations have pro- In 1994, Bernd Groner and colleagues (Wakao et al. vided insight into many of STAT5’s functions. Disrup- 1994), then at the Friedrich Miescher Institute in Basel, tion of cytokine signaling through STAT5 results in a cloned a cDNA from lactating ovine mammary tissue variety of cell-specific effects, ranging from a defective that encoded a transcription factor promoting prolactin- immune system and impaired erythropoiesis, the com- induced transcription of milk protein genes in mammary plete absence of mammary development during preg- epithelium. -
Type II Enteropathy-Associated T-Cell Lymphoma Features a Unique Genomic Profile with Highly Recurrent SETD2 Alterations
ARTICLE Received 23 Mar 2016 | Accepted 15 Jul 2016 | Published 7 Sep 2016 DOI: 10.1038/ncomms12602 OPEN Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations Annalisa Roberti1, Maria Pamela Dobay2, Bettina Bisig1, David Vallois1, Cloe´ Boe´chat1, Evripidis Lanitis3, Brigitte Bouchindhomme4, Marie- Ce´cile Parrens5,Ce´line Bossard6, Leticia Quintanilla-Martinez7, Edoardo Missiaglia1,2, Philippe Gaulard8 & Laurence de Leval1 Enteropathy-associated T-cell lymphoma (EATL), a rare and aggressive intestinal malignancy of intraepithelial T lymphocytes, comprises two disease variants (EATL-I and EATL-II) differing in clinical characteristics and pathological features. Here we report findings derived from whole-exome sequencing of 15 EATL-II tumour-normal tissue pairs. The tumour suppressor gene SETD2 encoding a non-redundant H3K36-specific trimethyltransferase is altered in 14/15 cases (93%), mainly by loss-of-function mutations and/or loss of the corresponding locus (3p21.31). These alterations consistently correlate with defective H3K36 trimethylation. The JAK/STAT pathway comprises recurrent STAT5B (60%), JAK3 (46%) and SH2B3 (20%) mutations, including a STAT5B V712E activating variant. In addition, frequent mutations in TP53, BRAF and KRAS are observed. Conversely, in EATL-I, no SETD2, STAT5B or JAK3 mutations are found, and H3K36 trimethylation is preserved. This study describes SETD2 inactivation as EATL-II molecular hallmark, supports EATL-I and -II being two distinct entities, and defines potential new targets for therapeutic intervention. 1 University Institute of Pathology, Service of Clinical Pathology, Centre Hospitalier Universitaire Vaudois, 25 rue du Bugnon, 1011 Lausanne, Switzerland. 2 SIB Swiss Institute of Bioinformatics – Quartier Sorge, baˆtiment Ge´nopode, 1015 Lausanne, Switzerland. -
Short-Form Thymic Stromal Lymphopoietin (Sftslp) Is the Predominant Isoform Expressed by Gynaecologic Cancers and Promotes Tumour Growth
cancers Article Short-Form Thymic Stromal Lymphopoietin (sfTSLP) Is the Predominant Isoform Expressed by Gynaecologic Cancers and Promotes Tumour Growth Loucia Kit Ying Chan 1,†, Tat San Lau 1,†, Kit Ying Chung 1, Chit Tam 1, Tak Hong Cheung 1, So Fan Yim 1, Jacqueline Ho Sze Lee 1 , Ricky Wai Tak Leung 2, Jing Qin 2, Yvonne Yan Yan Or 3, Kwok Wai Lo 3 and Joseph Kwong 1,4,* 1 Department of Obstetrics of Gynaecology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; [email protected] (L.K.Y.C.); [email protected] (T.S.L.); [email protected] (K.Y.C.); [email protected] (C.T.); [email protected] (T.H.C.); [email protected] (S.F.Y.); [email protected] (J.H.S.L.) 2 School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sen University, Shenzhen 510006, China; [email protected] (R.W.T.L.); [email protected] (J.Q.) 3 Department of Anatomical and Cellular Pathology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; [email protected] (Y.Y.Y.O.); [email protected] (K.W.L.) 4 School of Medicine, Faculty of Medicine and Health Sciences, Keele University, Newcastle-under-Lyme ST5 5BG, UK * Correspondence: [email protected]; Tel.: +852-3505-2801 † These authors contributed equally to this work. Citation: Chan, L.K.Y.; Lau, T.S.; Simple Summary: Cytokines are a group of small proteins in the body that play an important part Chung, K.Y.; Tam, C.; Cheung, T.H.; in boosting the immune system. -
Thymic Stromal Lymphopoietin Interferes with the Apoptosis of Human Skin Mast Cells by a Dual Strategy Involving STAT5/Mcl-1 and JNK/Bcl-Xl
cells Article Thymic Stromal Lymphopoietin Interferes with the Apoptosis of Human Skin Mast Cells by a Dual Strategy Involving STAT5/Mcl-1 and JNK/Bcl-xL Tarek Hazzan, Jürgen Eberle, Margitta Worm * and Magda Babina * Department of Dermatology, Venerology and Allergy, Charité—Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany * Correspondence: [email protected] (M.W.); [email protected] (M.B.); Tel.: +49-30-450518238 (M.B.); Fax: +49-30-450518900 (M.B.) Received: 10 July 2019; Accepted: 1 August 2019; Published: 5 August 2019 Abstract: Mast cells (MCs) play critical roles in allergic and inflammatory reactions and contribute to multiple pathologies in the skin, in which they show increased numbers, which frequently correlates with severity. It remains ill-defined how MC accumulation is established by the cutaneous microenvironment, in part because research on human MCs rarely employs MCs matured in the tissue, and extrapolations from other MC subsets have limitations, considering the high level of MC heterogeneity. Thymic stromal lymphopoietin (TSLP)—released by epithelial cells, like keratinocytes, following disturbed homeostasis and inflammation—has attracted much attention, but its impact on skin MCs remains undefined, despite the vast expression of the TSLP receptor by these cells. Using several methods, each detecting a distinct component of the apoptotic process (membrane alterations, DNA degradation, and caspase-3 activity), our study pinpoints TSLP as a novel survival factor of dermal MCs. TSLP confers apoptosis resistance via concomitant activation of the TSLP/ signal transducer and activator of transcription (STAT)-5 / myeloid cell leukemia (Mcl)-1 route and a newly uncovered TSLP/ c-Jun-N-terminal kinase (JNK)/ B-cell lymphoma (Bcl)-xL axis, as evidenced by RNA interference and pharmacological inhibition.